Back grey_arrow_rt.gif
 
 
Ziagen 300 mg scored tablet facilitates pediatric treatment of infection with HIV
 
 
  On December 19, 2008 FDA approved Ziagen (abacavir) 300 mg scored tablets with corresponding dosing information for pediatric patients weighing 14 kg or more using the scored tablet.
 
The Dosage and Administration and the Clinical Pharmacology sections were revised as follows:
 
2 DOSAGE AND ADMINISTRATION
2.2 Pediatric Patients _The recommended oral dose of ZIAGEN Oral Solution in HIV_1_infected pediatric patients >3 months of age is 8 mg/kg twice daily (up to a maximum of 300 mg twice daily) in combination with other antiretroviral agents.
 
ZIAGEN is also available as a scored tablet for HIV_1_infected pediatric patients weighing >14 kg for whom a solid dosage form is appropriate. Before prescribing ZIAGEN Tablets, children should be assessed for the ability to swallow tablets. If a child is unable to reliably swallow ZIAGEN Tablets, the oral solution formulation should be prescribed. The recommended oral dosage of ZIAGEN Tablets for HIV_1_infected pediatric patients is presented in Table 1.

total-1.gif

12 CLINICAL PHARMACOLOGY
12.3 Pharmacokinetics
Pediatric Patients: The pharmacokinetics of abacavir have been studied after either single or repeat doses of ZIAGEN in 68 pediatric patients. Following multiple_dose administration of ZIAGEN 8 mg/kg twice daily, steady-state AUC (0-12 hr) and Cmax were 9.8 ± 4.56 mcg„hr/mL and 3.71 ± 1.36 mcg/mL (mean ± SD), respectively [see Use in Specific Populations (8.4)]. In addition, to support dosing of Ziagen scored tablet (300 mg) for pediatric patients 14 - > 30 kg, analysis of actual and simulated pharmacokinetic data indicated comparable exposures are expected following administration of 300 mg scored tablet and the 8 mg/kg dosing regimen using oral solution. Ziagen. a member of the Nucleoside Reverse Transcriptase Inhibitor (NRTI) class, is a product of GlaxoSmithKline.
 
Richard Klein _Office of Special Health Issues _Food and Drug Administration Kimberly Struble _Division of Antiviral Drug Products _Food and Drug Administration
 
 
 
 
  icon paper stack View Older Articles   Back to Top   www.natap.org